A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements

A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements

Janus kinase (JK) inhibitors block the intracellular signaling pathways that are responsible for the synthesis of proinflammatory cytokines and mediators, which in turn cause the activation of pain receptors and central sensitization (CS). It is suggested that JK inhibitors can rapidly eliminate pai...

Full description

Bibliographic Details
Main Authors: A. E. Karateev, E. S. Filatova, E. Yu. Pogozheva, V. N. Amirdzhanova, E. L. Nasonov, A. M. Lila, V. I. Mazurov, A. Yu. De, A. A. Baranov, N. A. Lapkina, G. V. Lukina, N. A. Kiryukhina, S. Yu. Davidyan, T. S. Salnikova, R. R. Samigullina, D. S. Chakieva, I. M. Marusenko, O. V. Semagina, M. Yu. Semchenkova, A. F. Davydova, E. V. Kalinina
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2020-05-01
Series:Современная ревматология
Subjects:
rheumatoid arthritis
chronic pain
central sensitization
tofacitinib
efficacy
safety
Online Access:https://mrj.ima-press.net/mrj/article/view/1010

Internet

https://mrj.ima-press.net/mrj/article/view/1010

Similar Items